Natriuretic Brain Peptide

CHICAGO — An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be beneficial for select candidates, though a pivotal study did not meet its primary efficacy outcome.

An autologous cell therapy was safe for patients with heart failure with reduced ejection fraction and showed a signal of benefit for patients with elevated baseline N-terminal pro-B-type natriuretic peptide, researchers reported.

Moderately symptomatic patients with HF with elevated peptides or prior HF hospitalization, while experiencing differing outcome trajectories, derived similar benefit from hemodynamic-guided management, a speaker reported.

Researchers in Brazil identified new echocardiographic parameters and biomarkers prognostic of poor cardiac event-free survival among patients with chronic Chagas disease, which affects up to 7 million worldwide.

Among patients with idiopathic pulmonary fibrosis, the effects of nintedanib plus sildenafil, as compared with nintedanib alone, on quality of life and FVC did not differ significantly between patients with and those without evidence of right heart dysfunction, according to subgroup analyses of the INSTAGE trial.